This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine-ER Tablets for Treatment of Stable Walking Deficits in Subjects With Post-ischemic Stroke.

Trial Profile

This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine-ER Tablets for Treatment of Stable Walking Deficits in Subjects With Post-ischemic Stroke.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Fampridine (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms MILESTONE
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 21 Nov 2016 Primary endpoint (Proportion of subjects who show at least a 20% improvement on the Two Minute Walk Test (2MinWT) at week 12) has not been met, as per an Acordia Therapeutics media release.
    • 21 Nov 2016 Results published in an Acorda Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top